Since the decision to biopsy was based on PSA level, some of the controls with PSA <3 ng/mL will have unidentified prostate cancer [34] (misclassification bias) but this would not affect our analysis of locally advanced versus localized cancers (as all cancers were biopsy confirmed). This evidence concerns the gene KLK3 and prostate carcinoma.